Life Sciences

  • April 17, 2026

    ITC Clears Apple's Redesigned Apple Watch For Import

    The U.S. International Trade Commission on Friday signed off on an administrative law judge's finding that Apple has sufficiently redesigned its smartwatch so it doesn't infringe Masimo Corp.'s patents and is therefore not bound by a 2023 import ban.

  • April 17, 2026

    Missed Deadline Fatal To Patient's Stapler Suit, 4th Circ. Says

    The Fourth Circuit ruled Friday that a surgery patient's missed expert disclosure deadline rightfully ended his case seeking to hold Johnson & Johnson subsidiary Ethicon Endo-Surgery LLC liable for allegedly faulty staples used in his procedure.

  • April 17, 2026

    Kenvue Says Shea & Cocoa Butter Oil Is Accurately Labeled

    Kenvue urged a New Jersey federal court to nix a proposed class action alleging its shea and cocoa butter oil is deceptively advertised, as it's primarily made with a petroleum byproduct, arguing Thursday the front label truthfully identifies it as an oil enriched with shea and cocoa butter. 

  • April 17, 2026

    3 Key Questions On Trump's Pharma Tariffs

    President Donald Trump recently announced 100% tariffs on certain imported pharmaceutical products, with opportunities for drug companies to lower their tariff rates to zero, but questions remain about the requirements for preferential treatment and abilities to administer the regime. Here, Law360 examines three open questions surrounding pharmaceutical tariffs' implementation.

  • April 17, 2026

    AI Health Co. Illegally Shared Genetic Data, Patients Say

    A healthcare company powered by artificial intelligence violated Illinois' genetic privacy law and other consumer protection laws by compelling a genetic testing business it acquired to disclose patients' genetic information, which it then shared through data agreements with pharmaceutical giants such as Eli Lilly and AbbVie, a lawsuit in Illinois federal court says.

  • April 17, 2026

    Judge Says Biotech Co. Can't Wipe Cancer Data, For Now

    A Texas state judge signed a temporary restraining order on Friday that stops Bellicum Pharmaceuticals Inc. and the consulting firm helping it oversee its dissolution from deleting cell therapy data that the Houston-based MD Anderson Cancer Center says belongs to it.

  • April 17, 2026

    Life Sciences Firm Says Ex-VP Took Trade Secrets To Rival

    A Massachusetts life sciences startup says a former vice president who left the company last fall, purportedly to care for his ill wife, instead took trade secrets with him to a new job at a California rival.

  • April 17, 2026

    Aramark Joins NJ Insulin Pricing Suits Against PBMs

    Aramark Services Inc. joined multidistrict litigation accusing CVS and pharmacy benefit managers of colluding to inflate the price of insulin.

  • April 17, 2026

    Polsinelli Sent Bogus Infringement Letters, Suits Say

    National law firm Polsinelli PC was accused of sending letters to two medical device companies with meritless claims of patent infringement, the companies claimed in a pair of malpractice suits.

  • April 17, 2026

    Latham Leads Kailera's $625M IPO In Obesity Drug Push

    Obesity biotech Kailera Therapeutics made its public debut Friday, raising $625 million in an upsized initial public offering that represents one of the largest biotech IPOs in recent years.

  • April 17, 2026

    Doc Says Texas Man Can't Sue Over Mailed Abortion Pills

    A Texas man suing his ex-girlfriend's out-of-state doctor for prescribing mail-order abortion pills can't prove that the doctor caused the wrongful death of their unborn child, the doctor told a federal court, saying the case should be dismissed because he's not responsible for the woman's actions. 

  • April 17, 2026

    Fed. Circ. Reverses $18M Penile Implant Trade Secret Win

    In a unanimous precedential decision, the Federal Circuit on Friday largely reversed a California jury's $18.3 million trade secret verdict over a penile implant, holding that the asserted secrets were already publicly disclosed or generally known and therefore not protectable.

  • April 16, 2026

    Trump Taps Ret. Rear Admiral Schwartz As New CDC Chief

    President Donald Trump on Thursday nominated Dr. Erica Schwartz, a retired rear admiral who served in the U.S. Coast Guard and as deputy surgeon general in the first Trump administration, to be the Centers for Disease Control and Prevention's next director.

  • April 16, 2026

    Wis. Supreme Court Upholds Pabst Asbestos Verdict

    The Wisconsin Supreme Court upheld a verdict in favor of the estate of a steamfitter exposed to asbestos through his work at a Pabst Brewing Co. brewery, saying Wednesday that the company still owed a duty of care to employees of independent contractors, but capped punitive damages to about $4.65 million.

  • April 16, 2026

    Fed. Circ. Says Judge Wrongly Axed Teva's $177M Eli Lilly Win

    The Federal Circuit ruled Thursday that a Massachusetts federal judge was wrong to overturn a $177 million jury verdict that Teva won against Eli Lilly & Co. on headache drug patents, finding that contrary to the judge's finding, the patents are not invalid.

  • April 16, 2026

    IV Device Redesign Not Enough To Lift Ban, CBP Says

    A U.S. medical device company's redesigned products used for intravenous drips are still barred from importation into the country, U.S. Customs and Border Protection said in an order released Thursday, with the agency unconvinced the new versions aren't still patent-infringing.

  • April 16, 2026

    USPTO Ends COVID Patent Appeals Program

    The U.S. Patent and Trademark Office has decided to end a program launched five years ago that aimed to prioritize and fast-track ex parte appeals of rejections on patent applications for inventions related to combating COVID-19.

  • April 16, 2026

    Katten Partner Rejoins Epstein Becker In DC For 3rd Time

    Epstein Becker Green LLP has rehired, for the third time, a healthcare transactional attorney who focuses his practice on guiding hospital systems, private equity-backed entities and professional practices on transactional matters and regulatory compliance.

  • April 15, 2026

    Consumer Cases Drive Class Action Spike, Report Says

    Federal class action filings spiked in 2025 after nearly a decade of relative stability, fueled by a surge in consumer protection lawsuits tied to data breaches, digital commerce and online accessibility claims, according to a new report from Lex Machina.

  • April 15, 2026

    Amneal Trims But Can't Nix AGs' Drug Price-Fixing Suit

    There is enough evidence from which a jury could conclude that Amneal Pharmaceuticals participated in a conspiracy to fix the price of an epilepsy medication, but not enough to show it participated in the overarching antitrust conspiracy alleged by dozens of state attorneys general, a Connecticut federal judge ruled Wednesday.

  • April 15, 2026

    Drugmaker Aquestive's Brass Sued Over FDA Setback

    Executives and directors of pharmaceutical company Aquestive Therapeutics Inc. were hit with a shareholder's derivative suit Wednesday accusing them of ignoring deficiencies in a research study for Aquestive's allergic reaction treatment, which eventually prompted the U.S. Food and Drug Administration to reject the company's new drug application.

  • April 15, 2026

    Ex-DOJ Antitrust Atty On Google Case Joins Wilson Sonsini

    A lead attorney on the U.S. Department of Justice Antitrust Division's monopolization cases against Google LLC who left the agency last week joined Wilson Sonsini Goodrich & Rosati PC in Washington, D.C., on Wednesday as a partner.

  • April 15, 2026

    Squires Passes On 10 Patent Challenges, Takes On 2 Others

    The newest bulk order from U.S. Patent and Trademark Office Director John Squires has rejected 10 petitions for America Invents Act patent reviews while granting a couple others, including a Google challenge to a patent owned by Headwater Research LLC.

  • April 15, 2026

    NC Judge Won't Undo $4M Philips Copyright Verdict

    A North Carolina federal judge has refused to erase a $4 million jury verdict against independent service organization Transtate Equipment Co. for violations of the Digital Millennium Copyright Act, saying trial evidence provided a "firm basis" to support the jury's statutory damages award.

  • April 15, 2026

    Willkie Adds O'Melveny Litigator To Los Angeles Office

    Willkie Farr & Gallagher LLP expanded its Los Angeles office with the recent addition of a litigator who moved her practice after nearly 15 years with O'Melveny & Myers LLP.

Expert Analysis

  • Series

    Watching Hallmark Movies Makes Me A Better Lawyer

    Author Photo

    I realize you may be judging me for watching, and actually enjoying, Hallmark Channel movies, but the escapism and storylines actually demonstrate qualities and actions that lead to an efficient, productive and positive legal practice, says Karen Ross at Tucker Ellis.

  • New Orphan Drug Law Provides A Key Fix For Pharma Cos.

    Author Photo

    The Consolidated Appropriations Act enacted last month restores the U.S. Food and Drug Administration's long-standing interpretation of "same disease or condition," related to orphan drug exclusivity, resolving years of regulatory uncertainty and litigation that have discouraged rare disease research, say attorneys at Spencer Fane.

  • When Trade Secret Litigation And Criminal Law Collide

    Author Photo

    An increasing convergence of trade secret litigation and white collar defense, especially with several recent criminal prosecutions from the Justice Department, should prompt businesses and counsel to adapt within the overlapping landscapes, says Kenneth Notter at MoloLamken.

  • Opinion

    PTAB Needs Reform To Protect Inventors From Larger Cos.

    Author Photo

    The Promoting and Respecting Economically Vital American Innovation Leadership Act is necessary because it will impose additional requirements on patent validity challenges and prevent large corporations from taking advantage of the Patent Trial and Appeal Board to overwhelm small inventors with repeated litigation, says Eb Bright at ExploraMed Development.

  • FDA User Fee Talks Offer Clues On Upcoming Reforms

    Author Photo

    As the U.S. Food and Drug Administration undergoes the User Fee Act reauthorization process and renegotiates its user fee agreements over the next several months, the agency's consultation meetings with relevant industries can shed light on the FDA's priorities, and provides stakeholders an opportunity to participate in the reform process, say attorneys at Holland & Knight.

  • Moderna Case Highlights Overlooked Hurdle In Biopharma IP

    Author Photo

    The recent settlement of the patent litigation involving Moderna's COVID-19 vaccine in Delaware federal court shows that patent portfolios covering enabling platform technologies can create significant freedom-to-operate risk even when their owners are not direct competitors developing the therapeutic product, says Olga Berson at Thompson Coburn.

  • FDA Framework For Personalized Therapies Raises Questions

    Author Photo

    The U.S. Food and Drug Administration's new plausible mechanism framework for developing individualized therapies reflects the agency's focus on rare-disease drugs, but numerous significant, unresolved issues cast uncertainty on how effective the framework will be in practice, say attorneys at Ropes & Gray.

  • Emissions Permits May Not Override Pollution Exclusions

    Author Photo

    Two recent coverage rulings from the Illinois Supreme Court and the Third Circuit suggest a trend among appellate courts to deny coverage under pollution exclusions, even when the emissions happened pursuant to a government permit, say attorneys at Simpson Thacher.

  • 5 Tips For Navigating Your Firm's All-Attorney Summit

    Excerpt from Practical Guidance
    Author Photo

    Law firm retreats should be approached strategically, as they present valuable opportunities to advance both the firm's objectives and attorneys' professional development through meaningful participation, building and strengthening internal relationships, and proactive follow-up, says James Argionis at Cozen O’Connor.

  • Series

    Coaching Soccer Makes Me A Better Lawyer

    Author Photo

    Coaching youth soccer for my 7-year-old son's team has sharpened how I communicate with clients, prepare witnesses, work within teams and think about leadership, making me a more thoughtful and effective lawyer in many ways, says Joshua Holt at Smith Currie.

  • Series

    Law School's Missed Lessons: The Human Element

    Author Photo

    Law school teaches you to quickly apply intellect and logic when handling a legal issue, but every fact pattern also involves a person, making the ability to balance expertise with empathy critical to the growth of relationships with clients, colleagues and adversaries, says Rachel Adcox at Adcox Strategies.

  • Avoid The Unexpected When Drafting License Agreements

    Author Photo

    The Delaware Court of Chancery's recent decision in Commave v. Zevrain raises several practice points for attorneys drafting commercial contracts, underscoring the importance of considering anti-assignment provisions, specific exclusions and potential carveouts when drafting license agreements or other commercial contracts, say attorneys at Hogan Lovells.

  • CMS Healthcare Enforcement Initiatives May Cause Disruption

    Author Photo

    The Centers for Medicare & Medicaid Services' recently announced enforcement actions against healthcare fraud mark a significant escalation, and CMS' prior approach in the hospice sector suggests that even compliant providers and suppliers should brace for impact, say attorneys at Morgan Lewis.

  • The Benefits Of Choosing A Niche Practice In The AI Age

    Author Photo

    As artificial intelligence becomes increasingly accessible, lawyers with a niche practice may stand out as clients seek specialized judgment that automation cannot replicate, but it is important to choose a niche that is durable, engaging and a good personal fit, says Daniel Borneman at Lowenstein Sandler.

  • How PBMs Can Adapt To Plan Sponsors' Disclosure Demands

    Author Photo

    As federal reforms, growing state regulation and litigation threats push plan sponsors to expect visibility into revenue streams, pharmacy benefit managers should leverage transparency strategically, including by simplifying how they get paid, offering clients audit-ready data and co-designing contracts that are easy for fiduciaries to explain and defend, says Kristie Blase at Frazer + Blase.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.